Clinical Trial Update: Bioequivalence Study of GZR18 Injection Before and After CMC Change [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of GZR18 injection before and after a CMC change; the trial targets obesity and type 2 diabetes and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• GZR18

Snippet

Sponsor: Gan & Lee Pharmaceuticals. | Conditions: Obesity&T2D | Phase 1 | Status: RECRUITING